Drug Abuse Aspects of HIV/AIDS (R21)
National Institutes of Health · Opportunity PA-07-309
Multiple Receipt Dates - See Link to Full Announcement for details.
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities
- Native American tribal organizations (other)
- Nonprofits with 501(c)(3), other than higher education
- Nonprofits without 501(c)(3)
- Private institutions of higher education
- For-profit organizations other than small businesses
- Small businesses
- Others
Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith-based or community-based organizations can apply.
About this opportunity
Purpose. This Funding Opportunity Announcement (FOA) using the Exploratory/Developmental Grant (R21) encourages drug abuse research that addresses the changing dynamics of the HIV/AIDS epidemic in the U.S., such as the increasing over-representation of minorities and women among new AIDS cases and role of heterosexual sex as a transmission route. Studies are needed to develop novel preventive interventions that more effectively address the evolving epidemic. Internationally, studies are needed on how to translate and adapt interventions that have proved effective in the U.S. to other communities and international settings, and to learn from other conditions and cultures to inform our understanding of the causes, consequences, and differences in HIV-associated risks, morbidity, and mortality in diverse populations. The Exploratory/ Developmental Grant (R21) is intended for early and conceptual research development, for example to assess the feasibility of a novel area of investigation or a new experimental system that has the potential to enhance health-related research. Such studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of innovative techniques, agents, methodologies, models or applications that could have major impact on a field of biomedical, behavioral, or clinical research. Applications for R21 awards should be for projects distinct from those supported through the traditional R01 mechanism. Long-term projects, or projects designed to increase knowledge in a well-established area, will not be considered for R21 awards. Applications submitted under the R21 mechanism should be exploratory and novel, and seek to break new ground or extend previous discoveries toward new directions or applications.
Similar grants still open
| Opportunity | Agency | Deadline | Award ceiling | Eligible |
|---|---|---|---|---|
| Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) | National Institutes of Health | August 18, 2026 23d left | — | Nonprofits |
| Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed) | National Institutes of Health | September 7, 2026 43d left | $499k | Nonprofits |
| Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed) | National Institutes of Health | September 7, 2026 43d left | — | Nonprofits |
| Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed) | National Institutes of Health | September 7, 2026 43d left | — | Nonprofits |